Volume 11, Number 7—July 2005
West Nile Virus Detection and Commercial Assays
Highlight and copy the desired format.
|EID||Tilley P, Zachary GA, Walle R, Schnee PF. West Nile Virus Detection and Commercial Assays. Emerg Infect Dis. 2005;11(7):1154-1155. https://dx.doi.org/10.3201/eid1107.041149|
|AMA||Tilley P, Zachary GA, Walle R, et al. West Nile Virus Detection and Commercial Assays. Emerging Infectious Diseases. 2005;11(7):1154-1155. doi:10.3201/eid1107.041149.|
|APA||Tilley, P., Zachary, G. A., Walle, R., & Schnee, P. F. (2005). West Nile Virus Detection and Commercial Assays. Emerging Infectious Diseases, 11(7), 1154-1155. https://dx.doi.org/10.3201/eid1107.041149.|
To the Editor: Roehrig and colleagues described the long-term persistence of immunoglobulin (Ig) M antibody in patients with West Nile virus (WNV) infection, as tested using an in-house Centers for Disease Control and Prevention (CDC) enzyme immunoassay (EIA) (1). This result suggests that interpreting WNV IgM results in subsequent years would be difficult. With the commercial availability and widespread use of US Food and Drug Administration–approved WNV IgM tests, we were concerned that this phenomenon might also occur with new tests. Thus in 2004, we initiated a follow-up study of patients infected during the inaugural (2003) WNV season in Alberta, Canada.
Fifty patients who were WNV IgM positive by 2 commercial IgM kits (West Nile virus capture EIAs, Focus Technologies, Cypress, CA, USA, and Panbio, Windsor, Queensland, Australia) during the fall of 2003 were contacted. Sera were recollected and tested for IgM and IgG antibodies to WNV with current kits from these 2 companies. Sera were also tested for hemagglutination-inhibiting (HI) antibodies to WNV (2).
Of 39 serum samples from 38 patients, 28 were positive, 5 were indeterminate, and 6 were negative with the Focus IgM kit. Twenty-one were positive, 3 were indeterminate, and 14 were negative with the Panbio IgM kit. All had WNV IgG antibodies detected by Focus and Panbio IgG kits. We detected HI antibodies to WNV in all patients, and titers in 12 were ≥320. The time course for IgM index values for the Focus IgM kit used in 2003 and 2004 is shown in the Figure.
These data show that when tests are conducted with newly available kits, as with the CDC in-house test, IgM antibody to WNV persists for ≥8 months in most patients. A single high HI titer is not helpful in identifying recent infection. In addition, the IgM test cannot differentiate between recent and past infections. Interpreting a positive IgM result in WNV-endemic areas will be complex because a positive WNV IgM result could indicate a current acute infection or a previous WNV infection even in a person with a different acute illness.
We thank M. O'Connor and the staff of the Medicine Hat Regional Hospital laboratory for assistance with specimen collection and transport.
This work was supported by Alberta Health and Wellness, Calgary, Alberta, Canada.
- Roehrig JT, Nash D, Maldin B, Labowitz A, Martin DA, Lanciotti RS, Persistence of virus-reactive serum immunoglobulin M antibody in confirmed West Nile virus encephalitis cases. Emerg Infect Dis. 2003;9:376–9.
- Beaty BJ, Calisher CH, Shope RE. Arboviruses. In: Schmidt NJ, Emmons RW, editors. Diagnostic procedures for viral, rickettsial, and chlamydial infections. 6th ed. Washington: American Public Health Association, 1989; p.797–856.
- Figure. . West Nile virus (WNV) immunoglobulin (Ig)M index values in serum specimens from 38 WNV case-patients detected in the fall of 2003. The assay was performed by using the Focus...
Please use the form below to submit correspondence to the authors or contact them at the following address:
Peter A.G. Tilley, Provincial Laboratory for Public Health, 3030 Hospital Drive, Calgary, Alberta, Canada T2N 4W4; fax: 403-283-0142
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: April 24, 2012
- Page last updated: April 24, 2012
- Page last reviewed: April 24, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)